Persistent psychosis after a single ingestion of 'ecstasy'.
Van Kampen
J
J
Department of Psychiatry, University of Toronto, ON, Canada.
Katz
M
M
D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D002188:Cannabis / Q000009:adverse effects; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D006213:Hallucinogens / Q000009:adverse effects; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects*; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011562:Psilocybin / Q000009:adverse effects; D011605:Psychoses, Substance-Induced / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D018490:Serotonin Agents / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006213:Hallucinogens; D013287:Illicit Drugs; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D000077152:Olanzapine; D010890:Pirenzepine; D011562:Psilocybin; D018490:Serotonin Agents; D017367:Selective Serotonin Reuptake Inhibitors